Neurofit has signed a contract to supply its medical artificial intelligence (AI) solutions, Neurofit Aqua and Neurofit Scale Pet, to the University of Washington, the company announced on Tuesday.
This deal marks a significant milestone in Neurofit’s U.S. market entry, following the establishment of its American subsidiary last October and the appointment of Josh Cohen as head of U.S. operations in December. The agreement is expected to pave the way for securing valuable references in the American market.
Neurofit Aqua is an advanced neuroimaging analysis software that rapidly quantifies brain MRI scans, assessing brain atrophy and white matter degeneration. The software generates tailored analysis reports by quantifying brain shrinkage and white matter changes typically observed in neurodegenerative conditions such as Alzheimer’s disease and vascular dementia.
Neurofit Scale Pet, a quantitative analysis software for positron emission tomography (PET) imaging, automatically calculates the standard uptake value ratio (SUVR) for various brain imaging biomarkers. These include Alzheimer’s disease indicators like amyloid beta and tau proteins, as well as dopamine and other Target radiotracers.
Bin Jun Gil, co-CEO of Neurofit, said that by supplying Neurofit Aqua and Neurofit Scale Pet to U.S. research institutions, the company has established a foothold for expanding its presence in the American market. He added that Neurofit plans to leverage this achievement to steadily broaden its distribution channels across the United States.
In addition to Neurofit Aqua and Neurofit Scale Pet, the company is poised to accelerate its expansion in the U.S. market. Last month, Neurofit received 510 (k) premarket notification clearance from the FDA for Neurofit Aqua AD Plus, a comprehensive brain imaging analysis solution for Alzheimer’s treatment.
